---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-270560"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2026-06-15T15:31:39+00:00"
generated_at: "2026-06-15T15:33:13.745943+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences raises $4M via private placement of pre-funded warrants and options

## Summary
- Sold 3.88M pre-funded warrants and Series A-1/A-2 options at $1.03 per unit, gross proceeds ~$4M.
- Pre-funded warrants exercisable at $0.0001; Series A-2 options at $0.91, immediately exercisable.
- Series A-1 options exercisable at $0.91 after stockholder approval, expire five years later.
- H.C. Wainwright acted as exclusive placement agent; 7% cash fee plus placement agent warrants.
- Net proceeds to be used for working capital and general corporate purposes; offering closed June 12, 2026.

## SEC filing metadata
- accession: 0001193125-26-270560
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2026-06-15T15:31:39+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000119312526270560/0001193125-26-270560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000119312526270560/rkda-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-270560
- JSON: https://secwatch.observer/filing/0001193125-26-270560.json
- Plain text: https://secwatch.observer/filing/0001193125-26-270560.txt

## Key facts
- Material Agreements
  Arcadia Biosciences, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $4 million (effective 2026-06-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional accredited investor
  - Value: approximately $4 million
  - Effective: 2026-06-11
  source text: On June 11, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Purchaser”) for the sale and issuance in a private placement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000119312526270560/0001193125-26-270560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.